US-based biopharmaceutical company, RAPT Therapeutics’ stock surged more than 63% during the pre-market trading session on the US stock market’s Nasdaq after GSK Plc announced its $2.2 billion equity value acquisition deal, according to the official filing.
RAPT Therapeutics’ stock jumped more than 63% to $57.45 during the premarket trading session on Nasdaq after the acquisition update, compared to $35.10 at the previous market close, according to MarketWatch data on Tuesday.
(This is a developing story. Please check back for updates.)
Read all stories by Anubhav Mukherjee
Disclaimer: This story is for educational purposes only. We advise investors to consult with certified experts before making any investment decisions, as market conditions can change rapidly and circumstances may vary.
Source link